Viral Vector QC Gaps: Why Gene Therapy Programs Stall Before Clinic
Fragmented viral vector QC can delay gene therapy development. rcAAV detection failures, identity mischaracterization, and siloed workflows are key pain points. Integrated orthogonal testing can reduce quality gaps and support IND preparation. Viral vectors drive the gene therapy revolution — yet quality control (QC) remains the industry's Achilles' heel. As AAV, lentiviral, and...
0 Commenti 0 condivisioni 92 Views 0 Anteprima
Sponsorizzato
Sponsorizzato